I was in the RucaPANC trial testing the PARP-1 inhibitor Rucaparib (Rubraca) for metastatic pancreatic cancer of either PDAC or PACC origin. Criteria included patients had to have failed one prior therapy and showed sensitivity to a platin-based regimen such as Folfirinox or Gemzar+cis-platin. I was responding very well on Folfirinox and had 24 cycles of it as well as 22 cycles of 5-FU+Leucovorin before entering the trial as study patient#1. Patients with somatic or germline BRCA1, BRCA2 or PALB2 mutations were eligible. I am (g)BRCA2 positive.